GeneDx Holdings Corp. (NASDAQ:WGS) CEO Katherine Stueland Sells 51,420 Shares

GeneDx Holdings Corp. (NASDAQ:WGS - Get Free Report) CEO Katherine Stueland sold 51,420 shares of the stock in a transaction on Tuesday, January 7th. The stock was sold at an average price of $94.48, for a total value of $4,858,161.60. Following the completion of the transaction, the chief executive officer now owns 1,720 shares in the company, valued at approximately $162,505.60. This represents a 96.76 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Katherine Stueland also recently made the following trade(s):

• On Thursday, January 2nd, Katherine Stueland sold 18,006 shares of GeneDx stock. The shares were sold at an average price of $78.18, for a total transaction of $1,407,709.08.
• On Monday, December 16th, Katherine Stueland sold 10,501 shares of GeneDx stock. The stock was sold at an average price of $76.75, for a total transaction of $805,951.75.
• On Monday, December 9th, Katherine Stueland sold 3,661 shares of GeneDx stock. The stock was sold at an average price of $76.37, for a total value of $279,590.57.
• On Monday, November 18th, Katherine Stueland sold 22,307 shares of GeneDx stock. The shares were sold at an average price of $70.34, for a total value of $1,569,074.38.
• On Friday, November 15th, Katherine Stueland sold 23,108 shares of GeneDx stock. The shares were sold at an average price of $70.48, for a total value of $1,628,651.84.
• On Tuesday, October 29th, Katherine Stueland sold 2,154 shares of GeneDx stock. The stock was sold at an average price of $66.60, for a total transaction of $143,456.40.

GeneDx Stock Performance

Shares of NASDAQ WGS traded down $7.19 during trading on Friday, reaching $89.38. 725,309 shares of the stock traded hands, compared to its average volume of 909,701. The company has a 50-day moving average of $78.01 and a 200-day moving average of $53.19. GeneDx Holdings Corp. has a 52-week low of $2.85 and a 52-week high of $98.87. The stock has a market capitalization of $2.46 billion, a P/E ratio of -28.74 and a beta of 2.02. The company has a debt-to-equity ratio of 0.25, a current ratio of 2.40 and a quick ratio of 2.27.

GeneDx (NASDAQ:WGS - Get Free Report) last released its quarterly earnings data on Tuesday, October 29th. The company reported $0.04 EPS for the quarter, beating the consensus estimate of ($0.21) by $0.25. The business had revenue of $76.90 million for the quarter, compared to the consensus estimate of $64.98 million. GeneDx had a negative net margin of 31.25% and a negative return on equity of 13.35%. The company's revenue was up 44.3% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.82) earnings per share. Analysts forecast that GeneDx Holdings Corp. will post -0.24 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on WGS shares. Wells Fargo & Company boosted their price target on shares of GeneDx from $34.00 to $75.00 and gave the stock an "equal weight" rating in a report on Wednesday, October 30th. TD Cowen boosted their target price on GeneDx from $75.00 to $118.00 and gave the stock a "buy" rating in a research note on Tuesday. The Goldman Sachs Group increased their price target on GeneDx from $54.00 to $70.00 and gave the company a "neutral" rating in a research report on Wednesday, October 30th. Finally, Craig Hallum boosted their price objective on GeneDx from $70.00 to $95.00 and gave the stock a "buy" rating in a research report on Wednesday, October 30th. Three equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. Based on data from MarketBeat.com, GeneDx currently has a consensus rating of "Moderate Buy" and a consensus price target of $70.67.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the business. Renaissance Technologies LLC bought a new position in shares of GeneDx in the second quarter valued at approximately $2,362,000. Chartwell Investment Partners LLC bought a new position in GeneDx in the 3rd quarter valued at $1,722,000. Charles Schwab Investment Management Inc. increased its holdings in shares of GeneDx by 304.3% in the third quarter. Charles Schwab Investment Management Inc. now owns 147,034 shares of the company's stock worth $6,240,000 after purchasing an additional 110,666 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC bought a new position in shares of GeneDx in the third quarter worth $325,000. Finally, Lisanti Capital Growth LLC purchased a new stake in shares of GeneDx in the third quarter worth $1,554,000. 61.72% of the stock is currently owned by hedge funds and other institutional investors.

GeneDx Company Profile

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.